Outside-In Signaling upon Assembly on Endothelial Cells of the Proteins of the Plasma Kallikrein/Kinin System.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1024-1024
Author(s):  
Fakhri Mahdi ◽  
Zia Shariat-Madar ◽  
Alvin Schmaier

Abstract Investigations from our laboratory have shown that there is a multiprotein receptor system on endothelial cells (HUVEC) consisting of gC1qR, uPAR, and cytokeratin 1 for high molecular weight kininogen (HK) and factor XII (XII) (Blood97:2342; 99:3585) that serves as a presentation receptor for prekallikrein (PK) activation. When PK binds to HK on HUVEC, it is activated to plasma kallikrein by the serine protease prolylcarboxypeptidase (JBC277:17962; Blood103:4554). HK is also known to have anti-proliferative and anti-angiogenic activity. We asked if there is outside-in signaling through this HUVEC receptor complex. Initial investigations determined if single chain urokinase (ScuPA) or XII stimulates Erk 1 and 2 (MAPK42 and 44) (MAPK) in HUVEC. Independently ScuPA (5–200 nM) or XII (15–200 nM) in the presence of 0.05 mM zinc ion stimulates HUVEC MAPK expression and it is blocked by 0.1 mM PD98059, 30 nM wortmann, or 0.05 mM LY294002. Two chain uPA or APMSF-treated ScuPA upregulates MAPK to the same extent as ScuPA. Similarly, XIIa or APMSF-treated XII upregulates MAPK like XII. Since HK, ScuPA, XII and vitronectin (VN) all bind to the same region on uPAR (JBC279:16621), studies focused on the role of uPAR in these activities. Mab3B10 to the HK, ScuPA, XII, and VN binding site on uPAR’s Domain 2 (D2) blocks ScuPA or XII upregulation of MAPK. Peptides LRG20, YLP20, PGS20, or FHN20 from uPAR’s D2 (L166-N200) block ScuPA or XII upregulation of MAPK. Similarly, HKa (1 micromolar) and peptides from the HK Domain 5 (G469-H498) HUVEC binding region (GGH18, HKH20) (JBC270:19256) block ScuPA- or XII-induced MAPK expression. Treatment of HUVEC with 5-20 mM methyl-beta-cyclodextran (MBCD) or fillipin (1 microgram/ml), agents known to disrupt lipid rafts, do not interfere with ScuPA- or XII-induced MAPK upregulation. These combined data indicate that zymogen ScuPA or XII, two proteins with growth factor regions, directly signal through uPAR to upregulate MAPK to possibly induce cellular proliferative activities. HK or its activated fragments bound to uPAR inhibits these potential growth promoting activities. These studies imply that HKa’s anti-proliferative and anti-angiogenic activities are mediated through its interaction with uPAR. These investigations also indicate that, in addition to a presentation complex for PK activation, the HUVEC multiprotein receptor complex for HK, XII, and ScuPA has an auto-regulating outside-in signaling system in endothelials cells.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1817-1817 ◽  
Author(s):  
Alvin H. Schmaier ◽  
Fakhri Mahdi ◽  
Robert Sitrin

Abstract Previous studies have shown that the multiprotein kininogen (HK) and factor XII (FXII) receptor complex on endothelial cells (HUVEC) that consists of gC1qR, uPAR, and cytokeratin 1 (Blood97:2342, 99:3585) allows for prekallikrein assembly and activation for bradykinin formation (Blood 103:4554). New studies show outside-in signaling through this HUVEC receptor complex. Single chain urokinase (ScuPA) or FXII in the presence of 0.05 mM zinc ion stimulates ERK1/2 (MAPK42 and 44) in HUVEC (Blood 106:Abstract 1024Blood 106:Abstract 2005). Furthermore, cleaved HK (HKa) or peptides from the HK domain 5 cell binding region block HUVEC ERK1/2 phosphorylation. The region on uPAR that mediates this signaling is the same 22 aa sequence on uPAR domain 2 that binds ScuPA, FXII, HK, and vitronectin (JBC 279:16621). ScuPA or FXII phosphorylation of ERK1/2 is blocked by 0.1 mM PD98059, 30 nM wortmann, or 0.05 mM LY294002. Additional investigations determined if ScuPA or FXII in the presence of zinc ion stimulate Akt phosphorylation (Ser473). Both ScuPA (5–200 nM) or FXII (15–200 nM) in the presence of 0.05 mM zinc ion stimulated HUVEC Akt phosphorylation and it is blocked by 30 nM wortmann or 0.05 mM LY294002. Investigations next determined if the same region on uPAR that mediated ERK1/2 phosphorylation participated in Akt phosphorylation. Peptide LRG20 (L166-D185)or PGS20 (P176-T195) from domain 2 of uPAR or peptides HVL20 (H471-K494), HKH20 (H479-H498) or FKL20 (F459-K478) from domain 5 of HK blocked ScuPA- or FXII-induced phosphorylation of Akt (Ser473). Since uPAR does not directly interact with intracellular pathways, further investigations determined the mechanism for outside-in signaling. Studies showed that two antibodies to beta-1-integrin (Mabs 2253 and 1987) blocked ScuPA- or FXII-induced phosphorylation of Akt (Ser473). Additional investigations showed that ScuPA- (16–64 nM) or FXII- (60–240 nM) induced cell proliferation in a concentration-dependent fashion and it was blocked by peptide LRG20 of uPAR or HVL24 of HK’s domain 5. Further, cell proliferation is blocked by PD98059, wortmann, LY294002, and Mab 2253 to beta-1-integrin. Similarly, cell growth as measured by BrdU incorporation was induced by ScuPA or FXII in a concentration-dependent fashion. BrdU incorporation was blocked by peptides LRG20 and HVL24 as well as PD98059, wortmann, LY294002, and Mab 2253 to beta-1-integrin. These combined studies indicate uPAR in the kininogen multiprotein complex serves as at least one focal point for outside-in signaling after ScuPA or FXII binding. Stimulation of this receptor through beta-1-integrin leads to phosphorylation of ERK1/2 and Akt (Ser473) and induces HUVEC growth and proliferation. These investigations indicate two novel findings: first, they indicate outside-in signaling pathways for the multiprotein receptor complex for ScuPA, FXII, and HK. Second, they describe at least one pathway for the anti-angiogenic and anti-proliferative activities of HKa and its domain 5 fragments. These investigations show that the multiprotein kininogen/FXII receptor complex influences both HUVEC cellular growth and proliferation as well as intravascular proteolytic activity leading to bradykinin formation, blood pressure control and modulation of thrombosis risk (Blood 108:192).


2013 ◽  
Vol 394 (3) ◽  
pp. 319-328 ◽  
Author(s):  
Jia Liu ◽  
Edward P. Feener

Abstract Diabetic retinopathy (DR) occurs, to some extent, in most people with at least 20 years’ duration of diabetes mellitus. The progression of DR to its sight-threatening stages is usually associated with the worsening of underlying retinal vascular dysfunction and disease. The plasma kallikrein-kinin system (KKS) is activated during vascular injury, where it mediates important functions in innate inflammation, blood flow, and coagulation. Recent findings from human vitreous proteomics and experimental studies on diabetic animal models have implicated the KKS in contributing to DR. Vitreous fluid from people with advanced stages of DR contains increased levels of plasma KKS components, including plasma kallikrein (PK), coagulation factor XII, and high-molecular-weight kininogen. Both bradykinin B1 and B2 receptor isoforms (B1R and B2R, respectively) are expressed in human retina, and retinal B1R levels are increased in diabetic rodents. The activation of the intraocular KKS induces retinal vascular permeability, vasodilation, and retinal thickening, and these responses are exacerbated in diabetic rats. Preclinical studies have shown that the administration of PK inhibitors and B1R antagonists to diabetic rats ameliorates retinal vascular hyperpermeability and inflammation. These findings suggest that components of plasma KKS are potential therapeutic targets for diabetic macular edema.


2005 ◽  
Vol 93 (02) ◽  
pp. 359-367 ◽  
Author(s):  
Noriko Kato ◽  
Takahide Okayama ◽  
Haruhiko Isawa ◽  
Masao Yuda ◽  
Yasuo Chinzei ◽  
...  

SummaryThe plasma kallikrein-kinin system inhibitor, haemaphysalin, from the hard tick, Haemaphysalis longicornis, was identified. It was found that haemaphysalin inhibited activation of the plasma kallikrein-kinin system by interfering with reciprocal activation between factor XII and prekallikrein. It did not, however, inhibit amidolytic activities of factor XIIa and kallikrein. Direct binding assay indicated that factor XII/XIIa and high molecular weight kininogen (HK) are the target molecules of haemaphysalin, and that Zn2+ ions are involved in the interactions of haemaphysalin with these target molecules. This suggests that haemaphysalin interacts with target molecules by recognizing their conformational changes induced by Zn2+ ions. Furthermore, haemaphysalin interacted with the fibronectin type II domain and domain D5, the cell binding domains of factor XII and HK, respectively. This finding suggests that haemaphysalin interferes with the association of factor XII and the prekallikrein-HK complex with a biologic activating surface by binding to these cell-binding domains, leading to inhibition of the reciprocal activation between factor XII and prekallikrein.


1999 ◽  
Vol 82 (08) ◽  
pp. 226-233 ◽  
Author(s):  
Rasmus Røjkjær ◽  
Zia Shariat-Madar ◽  
Alvin Schmaier

IntroductionFor the last 25 years, most investigators in the field of plasma kallikrein/kinin have accepted the contact activation hypothesis by factor XII initiates plasma kallikrein/kinin system activation by binding to a physiologic, negatively-charged surface. This hypothesis forms the basis of the common surface-based coagulation assays, such as the activated partial thromboplastin time (aPTT). Also, it may be the mechanism by which the plasma kallikrein/kinin system becomes activated in vivo when exposed to artificial surfaces, such as those used in medical interventions, and following infection.A physiologic, negatively-charged surface, however, capable of initiating the activation of this system has never been convincingly described. This fact questions the role of this system in vivo. Sulfatides, phospholipids, cholesterol sulfate, chondroitin sulfate, heparins, and other glycosaminoglycans have been proposed as physiologic negatively charged surfaces. The autoactivation of factor XII, which can take several hours depending on the surface, leads to prekallikrein (PK) activation. Kallikrein formation reciprocally activates more factor XII in a reaction that is at least 1,000-fold faster than autoactivation. In addition to the surface, the rate of initiation and amplification of this system is accelerated by high molecular weight kininogen (HK). Activation of the zymogens factor XII and PK result in enzymes that have been proposed to contribute to factor XI activation (coagulation), complement activation, bradykinin (BK) liberation, fibrinolysis, and granulocyte activation in vitro.It is well known, however, that clinical deficiencies in factor XII, PK, and HK are not associated with bleeding, even though these deficiencies markedly prolong surfaced-activated coagulation assays for hemostasis. This information indicates that this system contributes little, if anything, to hemostasis. Recently, this field has been thoroughly reviewed.1,2 The purpose of this report is to present a new hypothesis for assembly and activation of this system on viable cell membranes and to begin to clarify these proteins’ roles in vivo.Over 10 years ago, our laboratory developed a working hypothesis to serve as an alternative to the factor XII autoactivation mechanism for the initiation of activation of the proteins of the plasma kallikrein/kinin system. We reasoned that, in vivo, it is the assembly of a multiprotein complex of these proteins on cell receptors that allows for localization and activation of this system. To prove that hypothesis, we sought to accomplish the following three things. First, we attempted to determine whether there is a receptor(s) for the proteins of this system on cell membranes. Second, we sought to show whether the assembly of the proteins of the plasma kallikrein/kinin system on cell membranes results in activation of PK and factor XII. Finally, we attempted to demonstrate biological activities associated with the activation of these proteins on cell membranes. The following report details this work and characterizes a new hypothesis for the assembly and activation of the proteins of the plasma kallikrein/kinin system.


2011 ◽  
Vol 392 (7) ◽  
Author(s):  
Julius F. Varano della Vergiliana ◽  
Sally Lansley ◽  
Ai Ling Tan ◽  
Jenette Creaney ◽  
Y.C. Gary Lee ◽  
...  

AbstractPleural inflammation underlies the formation of most exudative pleural effusions and the plasma kallikrein-kinin system (KKS) is known to contribute. Mesothelial cells are the predominant cell type in the pleural cavity, but their potential role in plasma KKS activation and BK production has not been studied. Bradykinin concentrations were higher in pleural fluids than the corresponding serum samples in patients with a variety of diseases. Bradykinin concentrations did not correlate with disease diagnosis, but were elevated in exudative effusions. It was demonstrated, using a range of primary and transformed mesothelial and mesothelioma cell lines, that cells assembled high molecular weight kininogen and plasma prekallikrein to liberate bradykinin, a process inhibited by novobiocin, a heat shock protein 90 (HSP90) inhibitor, cysteine, bradykinin and protamine sulphate. Of the common plasma prekallikrein activators, mesothelial cells expressed HSP90, but not prolylcarboxypeptidase or Factor XII. Calcium mobilisation was induced in some mesothelium-derived cell lines by bradykinin. Des-Arg9-bradykinin was inactive, indicating that mesothelial cells are responsive to bradykinin, mediated via the bradykinin receptor subtype 2. In summary, pleural mesothelial cells support the assembly and activation of the plasma KKS by a mechanism dependent on HSP90, and may contribute to KKS-mediated inflammation in pleural disease.


1992 ◽  
Vol 67 (02) ◽  
pp. 219-225 ◽  
Author(s):  
Walter A Wuillemin ◽  
Miha Furlan ◽  
Hans Stricker ◽  
Bernhard Lämmle

SummaryThe plasma of a healthy woman was found to contain half normal factor XII (FXII) antigen level (0.46 U/ml) without any FXII clotting activity (<0.01 U/ml). The variant FXII in this plasma, denoted as FXII Locarno, was partially characterized by immunological and functional studies on the proposita’s plasma. FXII Locarno is a single chain molecule with the same size (M r = 80 kDa) as normal FXII. Isoelectric focusing suggested an excess of negative charge in the variant FXII as compared to normal FXII. In contrast to FXII in normal plasma, FXII Locarno was not proteolytically cleaved upon prolonged incubation of proposita’s plasma with dextran sulfate. Adsorption to kaolin was similar for both, abnormal and normal FXII. Incubation of the proposita’s plasma with dextran sulfate and exogenous plasma kallikrein showed normal cleavage of FXII Locarno outside of the tentative disulfide loop Cys340-Cys467, but only partial cleavage within this disulfide loop. Furthermore, plasma kallikrein-cleaved abnormal FXII showed neither amidolytic activity nor proteolytic activity against factor XI and plasma prekallikrein.These results suggest a structural alteration of FXII Locarno, affecting the plasma kallikrein cleavage site Arg353-Val354 and thus formation of activated FXII (a-FXIIa).


Sign in / Sign up

Export Citation Format

Share Document